Biocon commercial rights on biosimilar adalimumab extends to global markets

Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from global markets.

New Delhi: Pharma major Biocon Tuesday said the company retains an economic interest in the global commercialisation of Hulio in-licensed by Mylan. "Following the successful approval and European launch of Hulio, (biosimilar adalimumab) in-licensed by our partner Mylan from Fujifilm Kyowa Kirin Biologics, the commercialisation rights have been extended from Europe to global markets," it said in a regulatory filing.

Read Also: Biocon, Lupin, Wockhardt, Cadila Healthcare lose Insurance Battle in Delhi High Court

Biocon, under the terms of its global partnership with Mylan for monoclonal antibodies, retains its economic interest in this expanded in-licensing arrangement and will gain a share of profits from global markets, it said.

"Biocon is committed to enable patient access to affordable biosimilars and this partnership accelerates that process," the company's spokesperson said in the filing.

Based in Bangalore the company manufactures generic active pharmaceutical ingredients (APIs) that are sold in over 120 countries across the globe, including the developed markets of the United States and Europe. It also manufactures novel biologics, as well as, biosimilar insulins and antibodies, which are sold in India as branded formulations.

The company's biosimilar products are also sold in both bulk and formulation forms in several emerging markets. In research services, Syngene International Limited (Syngene), a publicly listed subsidiary of Biocon, is engaged in the business of integrated end-to-end drug discovery and development services.

Read Also: Biocon gets 6 USFDA observations for Bengaluru plant